DME Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Graphic Packaging
GPK
|
+$61M |
| 2 |
Capri Holdings
CPRI
|
+$48.1M |
| 3 |
Acadia Healthcare
ACHC
|
+$46.9M |
| 4 |
Centene
CNC
|
+$40.4M |
| 5 |
Spectrum Brands
SPB
|
+$37.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Seadrill
SDRL
|
+$48M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$17.7M |
| 3 |
Weatherford International
WFRD
|
+$15.8M |
| 4 |
Nexstar Media Group
NXST
|
+$14.6M |
| 5 |
Kyndryl
KD
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 37.66% |
| 2 | Healthcare | 14.27% |
| 3 | Energy | 14.18% |
| 4 | Industrials | 10.82% |
| 5 | Financials | 7.14% |
Similar funds
DME Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, DME Capital Management held 45 positions worth $2.85B, up 12% from $2.54B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
DME Capital Management deployed $334M of net new capital in Q4 2025, opening 8 new positions and adding to 11 existing holdings. Its largest new stake was Spectrum Brands: 663,890 shares worth $39.2M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, down from 41% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $17.7M trimmed.
- DME Capital Management's largest Q4 2025 buy was Spectrum Brands: 663,890 shares worth $39.2M.
- DME Capital Management added most to Graphic Packaging in Q4 2025, an estimated $61M increase.
- DME Capital Management's biggest Q4 2025 reduction was Teva Pharmaceuticals, cutting an estimated $17.7M.
- DME Capital Management fully exited Seadrill in Q4 2025, selling an estimated $48M.
- DME Capital Management's ten largest holdings make up 65% of its $2.85B portfolio in Q4 2025.
- DME Capital Management opened 8 new positions and closed 4 in Q4 2025.
- DME Capital Management's portfolio value rose 12% quarter-over-quarter to $2.85B.
Based on DME Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.